Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

PSA testing without clinical indication for prostate cancer in relation to socio-demographic and clinical characteristics in the Danish Diet, Cancer and Health Study.

Karlsen RV, Larsen SB, Christensen J, Brasso K, Friis S, Tjønneland A, Dalton SO.

Acta Oncol. 2013 Nov;52(8):1609-14. doi: 10.3109/0284186X.2013.831474. Epub 2013 Aug 27.

PMID:
23978293
2.

Variation in general practice prostate-specific antigen testing and prostate cancer outcomes: an ecological study.

Hjertholm P, Fenger-Grøn M, Vestergaard M, Christensen MB, Borre M, Møller H, Vedsted P.

Int J Cancer. 2015 Jan 15;136(2):435-42. doi: 10.1002/ijc.29008. Epub 2014 Jun 12.

3.

Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.

Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J.

Eur Urol. 2015 Sep;68(3):354-60. doi: 10.1016/j.eururo.2014.12.006. Epub 2014 Dec 31.

PMID:
25556937
4.

Obesity and prostate cancer screening among African-American and Caucasian men.

Fowke JH, Signorello LB, Underwood W 3rd, Ukoli FA, Blot WJ.

Prostate. 2006 Sep 15;66(13):1371-80.

PMID:
16752375
5.

Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.

Hattangadi JA, Chen MH, D'Amico AV.

BJU Int. 2012 Dec;110(11):1636-41. doi: 10.1111/j.1464-410X.2012.11354.x. Epub 2012 Jul 3.

6.

Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort.

Larsen SB, Brasso K, Iversen P, Christensen J, Christiansen M, Carlsson S, Lilja H, Friis S, Tjønneland A, Dalton SO.

Eur J Cancer. 2013 Sep;49(14):3041-8. doi: 10.1016/j.ejca.2013.04.015. Epub 2013 May 17.

7.

Correlates of prostate-specific antigen testing in a large multiethnic cohort.

Haque R, Van Den Eeden SK, Jacobsen SJ, Caan B, Avila CC, Slezak J, Sternfeld B, Loo RK, Quinn VP.

Am J Manag Care. 2009 Nov;15(11):793-9.

8.

Factors influencing primary care physicians' decision to order prostate-specific antigen (PSA) test for men without prostate cancer.

Hayat Roshanai A, Nordin K, Berglund G.

Acta Oncol. 2013 Nov;52(8):1602-8. doi: 10.3109/0284186X.2012.762998. Epub 2013 Feb 19.

PMID:
23421929
9.

Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.

Moul JW, Sesterhenn IA, Connelly RR, Douglas T, Srivastava S, Mostofi FK, McLeod DG.

JAMA. 1995 Oct 25;274(16):1277-81.

PMID:
7563532
10.

Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase.

Kristal AR, Chi C, Tangen CM, Goodman PJ, Etzioni R, Thompson IM.

Cancer. 2006 Jan 15;106(2):320-8.

11.

Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans?

Hudson MA, Luo S, Chrusciel T, Yan Y, Grubb RL 3rd, Carson K, Scherrer JF.

Urol Oncol. 2014 Jan;32(1):34.e9-18. doi: 10.1016/j.urolonc.2013.01.003. Epub 2013 Mar 15.

12.
13.

Prostate cancer mortality in the Finnish randomized screening trial.

Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, Stenman UH, Kujala P, Auvinen A.

J Natl Cancer Inst. 2013 May 15;105(10):719-25. doi: 10.1093/jnci/djt038. Epub 2013 Mar 11.

PMID:
23479454
14.

Treatment with curative intent and survival in men with high-risk prostate cancer. A population-based study of 11 380 men with serum PSA level 20-100 ng/mL.

Ladjevardi S, Berglund A, Varenhorst E, Bratt O, Widmark A, Sandblom G.

BJU Int. 2013 Mar;111(3):381-8. doi: 10.1111/j.1464-410X.2012.11320.x. Epub 2012 Jul 3.

15.

Predictors of repeated PSA testing among black and white men from the Maryland Cancer Survey, 2006.

Zhu Y, Sorkin JD, Dwyer D, Groves C, Steinberger EK.

Prev Chronic Dis. 2011 Sep;8(5):A114. Epub 2011 Aug 15.

16.

Prostate-specific antigen utilization in Ontario: extent of testing in patients with and without cancer.

Bunting PS, Chong N, Holowaty EJ, Goel V.

Clin Biochem. 1998 Aug;31(6):501-11.

PMID:
9740973
17.

Factors prompting PSA-testing of asymptomatic men in a country with no guidelines: a national survey of general practitioners.

Drummond FJ, Carsin AE, Sharp L, Comber H.

BMC Fam Pract. 2009 Jan 12;10:3. doi: 10.1186/1471-2296-10-3.

18.

Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.

Carlsson S, Assel M, Sjoberg D, Ulmert D, Hugosson J, Lilja H, Vickers A.

BMJ. 2014 Mar 28;348:g2296. doi: 10.1136/bmj.g2296.

19.

Prostate cancer and prostate-specific antigen (PSA) screening in Austria.

Vutuc C, Schernhammer ES, Haidinger G, Waldhör T.

Wien Klin Wochenschr. 2005 Jul;117(13-14):457-61.

PMID:
16091872
20.

Prostate-specific antigen testing in general practice: a survey among 325 general practitioners in Denmark.

Jønler M, Eddy B, Poulsen J.

Scand J Urol Nephrol. 2005;39(3):214-8.

PMID:
16118092

Supplemental Content

Support Center